Damora Therapeutics redomiciles from Delaware to Cayman Islands
DMRA•Damora Therapeutics completes Cayman redomestication
Damora Therapeutics completed a redomestication to the Cayman Islands from Delaware, effective July 16, 2026.
Each Delaware common share converted into one Cayman ordinary share with $0.00001 par value; preferred shares converted one-for-one into corresponding series.
Nasdaq listing continues under DMRA; a new CUSIP, G2646Y104, takes effect July 20, 2026.
The reorganization leaves the business, management, obligations, assets and liabilities unchanged.
